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Open access uPurpose: It has been shown that a cumulative dose of P87 Gy (EQD2) of external beam radiotherapy
(EBRT) and image guided adaptive brachytherapy (IGABT) to the high risk clinical target volume (HR
CTV) confer a local control rate >95% in locally advanced cervical cancer. This study examines the dose
distribution within the HR CTV and intermediate (IR) CTV in patients with cervical cancer treated with
deﬁnitive EBRT +/ concomitant chemotherapy and MRI-based IGABT between patients with local recur-
rence (LR) and patients in continuous complete local remission (CCLR).
Material and methods: From 1998 to 2010, 265 patientswere treatedwith deﬁnitive EBRT +/ concomitant
chemotherapy and IGABT. Twenty-four LRs were documented. For the statistical analysis all patients with
LR were matched to patients in CCLR from our database according to the following criteria: FIGO stage,
histology, lymph node status, tumour size and chemotherapy.
DVH parameters (D50, D90, D98, D100) were reported for HR CTV and IR CTV. In order to report the mini-
mumdose in the regionwhere the recurrenceoccurred, theHRCTV/IRCTVweredivided into four quadrants
on transversal planes. The minimum dose at the HR CTV/IR CTV contour was measured (within the corre-
sponding quadrant closest to the LR) in the treatment planning system. Ameanminimumpoint dose (MPD)
was calculated byaveraging thesemeasurements on four consecutive slices at the level of the recurrence for
each of the 4 brachytherapy fractions. EQD2 doses were calculated by summation of all BT and external
beam therapy fractions.
For each matched patient in the control group the measurements were performed on the same quadrant
and at the same level.
Results: Sufﬁcient image data were available for 21 LRs. Eight central failures and 13 non-central failures
were observed. The mean D90 and D100 for HR CTV were 77 Gy and 61 Gy for patients with LR and
95 Gy and 71 Gy for patients in CCLR, respectively (p < 0.01). The MPD for HR CTV was 72 Gy for patients
in the LR arm and 99 Gy for patients in the CCLR arm (p < 0.01). In the LR arm seven patients had a D90
for HR CTVP87 Gy, however, in only three patients the MPD wasP87 Gy.
Conclusion: This study demonstrated signiﬁcant differences in local outcome according to the delivered
dose. In 85% of the LRs systematic lowdose regionswith less than 87 Gywere found atHR CTV contour. Sys-
tematic low dose regions leading to local recurrence could be detected even if a D90 HR CTVP87 Gy was
applied. In addition to DVH parameters, inspection of the spatial dose distribution remains a key point in
dose prescription.
 2011 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.
Radiotherapy and Oncology 100 (2011) 468–472Local tumour control is the major endpoint in image-guided
adaptive brachytherapy (IGABT) [1]. Since the publication of the
GEC-ESTRO recommendations [2,3] IGABT is becoming increas-
ingly introduced into clinical practice. First monoinstitutionaladiotherapy, Medical Univer-
ringer Gürtel, A-1090 Vienna,
.P. Schmid).
nder CC BY-NC-ND license.series demonstrated an increased therapeutic ratio when com-
pared to conventional 2D X-ray based brachytherapy [4–7]. Previ-
ous reports from our group described a signiﬁcant dependence of
local tumour control on D90 and D100 for HR CTV. Especially the
D90 for HR CTV seems to be a reliable parameter for predicting lo-
cal tumour control and can be used in clinical practice. It was
shown that if a D90P 87 Gy is applied, a local tumour control rate
greater than 95% is achievable. The D100 appears to be also an
indicator for local tumour control but is highly dependent on
uncertainties [8,9].
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ways refer to the whole contoured volume irrespective of dose
variations. This means that clinically relevant topographic (sub-
)areas within the HR CTV such as lateral tumour extension in the
parametrial space could be underrepresented or even not reﬂected
by DVH parameters due to the heterogeneous dose proﬁle in
brachytherapy. It may be assumed that such short comings in
the spatial dose distribution will impact on local tumour control.
The primary goal of the study is to retrospectively investigate the
dose in the area where the local recurrence occurred and to deter-
mine whether a low dose detected by the DVH parameters is topo-
graphically related to the area of the LR and reﬂected by the
regional dose in the area of LR. The regional dose in the area of the
local recurrence will be compared to the dose delivered in a similar
region in patients with complete continuous local remission (CCLR)
within a matched pair analysis. The secondary goal is to report pat-
terns of failure and clinical outcome. The tertiary goal is to analyse
the feasibility and clinical relevance of the D50 and D98.Material and methods
Patients and treatment
From 1998 to 2010, 265 patients with uterine cervical cancer
were treated at the Medical University of Vienna with EBRT (+/
chemotherapy) and IGABT in curative intent. Until the end of
2010 24 LRs were documented. Inclusion criteria for this study
were the availability of complete MRI or CT datasets at the time
of diagnosis, at the time of each brachytherapy fraction and at
the time of LR.
Intended treatment consisted of 45–50 Gy EBRT delivered in 25–
28 fractions with or without concomitant cisplatin based chemo-
therapy (40 mg/m2 of body surface per week for ﬁve weeks) and
three to six fractions of 5–7 Gy HDR brachytherapy using tandem
ring applicators +/ interstitial needles and/or a combination of tan-
dem and vaginal cylinders +/ interstitial needles. MRI imaging,
contouring and treatment planning were performed as described
in earlier publications [2,3,10–14]. Follow-up investigations includ-
ing clinical examination and MRI and/or CT were performed every
three months for the ﬁrst two years and twice annually for the next
three years. Hence, all LRs were assessed by clinical examination,
imaging studies (MRI and/or CT) and additionally by biopsy, if acces-
sible. IfMRIwasnot available at the timeof LR, CT togetherwith clin-
ical examination was accepted for the deﬁnition of the area of LR
(quadrant and level).Classiﬁcation of patterns of failure
LRs were classiﬁed as central recurrence (1) if the LR was local-
ized within the uterine cervix, the uterine corpus and/or within the
upper vagina or (2) if the LR captured the whole small pelvis and a
side-speciﬁc attribution was not possible. LRs were described as
non-central in case of LR at the parametrial space, the pelvic wall
and or distal vagina. Non-central recurrences located at the para-
metrial space and/or at the pelvic wall were distinguished into
ipsilateral and contralateral recurrences. Non-central recurrences
were classiﬁed as ipsilateral if the main tumour load outside the
uterine cervix at the time of diagnosis and the LR were situated
on the same side. Non-central recurrences were classiﬁed as con-
tralateral if the main tumour load outside the uterine cervix at
the time of diagnosis and the LR were situated on opposite sides.Fig. 1. Example of the assessment of the minimum point dose based on the case
presented in Fig. 2. T2-weighted MR image from the ﬁrst brachytherapy fraction.
The local recurrence was located on the right pelvic wall. The point dose assessment
was performed correspondingly in the right quadrant. The white arrow indicates
the area of the minimum point dose.DVH and point dose analysis
DVH parameters (D50, D90, D98, D100) for HR CTV and IR CTV
were reported for all patients. In order to report the minimum dosein the region where the recurrence occurred, the target volumes
were divided into four quadrants on transversal planes in a way,
so that two quadrants covered each one complete parametrial side
and the remaining two quadrants covered the spaces anterior and
posterior to the cervix (Figs. 1 and 2). The minimum dose at the
target volume contour was measured at the corresponding quad-
rant closest to the LR in the treatment planning system. These
measurements were performed on four consecutive slices (the
MRI-slice thickness was 0.5 cm) at the level of the recurrence for
each brachytherapy fraction separately – for example in case of a
non-central recurrence treated with four fractions of HDR brachy-
therapy, 4  4 minimum point doses per target volume were mea-
sured. A mean minimum point dose (MPD) was calculated by
averaging these measurements. Biologically normalized EQD2
doses were calculated by summation of all four BT fractions and
external beam therapy.
In case of a central recurrence the MPD was calculated for both
parametrial sides and the lower of these two values was taken as
the ﬁnal MPD – this means that for central recurrences in total
eight minimum point doses (four on each parametrial side) were
measured per fraction, however, only the MPD with lower dose
was used.Matched-pair analysis
To compare the MPD, DVH parameters and clinical outcome of
all patients with LR to a comparable group of patients in CCLR, each
patient with LR was matched to one patient in CCLR. The patient
database at the Medical University of Vienna consists of 265 pa-
tients treated from 1998 to 2010 with deﬁnitive EBRT (+/ chemo-
therapy) and IGABT. Each patient with LR was matched to a speciﬁc
patient in CCLR treated between 2001 and 2008 according to the
following matching criteria: FIGO stage (any tumour stage), histol-
ogy (any histology), lymph node status (positive vs. negative), tu-
mour size (P5 cm vs. <5 cm) at diagnosis, chemotherapy (yes vs.
no).
For each matched patient in the CCLR group the MPD was as-
sessed following the same method as for patients with LR. The
quadrant and the level for measuring the minimum point doses
in patients in CCLR were deﬁned according to the speciﬁc situation
of the matched patient with LR in regard of the initial tumour
spread and the topography of the LR – for example in case of a pa-
tient in CCLR matched to a patient with an ipsilateral non-central
Fig. 2. Example from the matched-pair analysis. Fig. 2a shows a patient from the local recurrence group and Fig. 2b shows the matched patient from the continuous complete
remission group at the time of diagnosis (1), at the time of the ﬁrst brachytherapy (BT) fraction (2) and with and without local recurrence (3). Both patients had a squamous
cell carcinoma, staged as FIGO III with a maximum tumour diameter P5 cm. Pelvic lymph nodes were involved in both cases. Both patients received concomitant cisplatin
chemotherapy. The patient from Fig. 2a was treated with 45 Gy external beam radiotherapy (EBRT) and three fractions of intracavitary brachytherapy during the ‘‘learning
period’’. A substantial low dose region occurred in the right parametrial space. The local recurrence was located in the right pelvic wall corresponding to the low dose regions,
as indicated by the white arrows. The D90 for HR CTV was 67.5 Gy and the MPD for HR CTV was 56.9 Gy. The patient from Fig. 2b was treated with 45 Gy EBRT and four
fractions of combined intracavitary and interstitial BT. The HR CTV was sufﬁciently covered by the 7 Gy isodose-line. No local recurrence was reported until the time of
analysis after a follow up time of 35 months. The D90 for HR CTV was 86 Gy and the MPD for HR CTV was 80 Gy. Black line – HR CTV. Inner white dotted line – 7 Gy isodose.
Outer white dotted line – 5 Gy isodose.
470 Local recurrences in cervical cancerLR at a pelvic wall the MPDwas calculated in the quadrant with the
main parametrial involvement (‘‘ipsilateral’’).Endpoints and statistical analysis
Descriptive statistics were performed for patient and treatment
characteristics and patterns of failure. Gross tumour volume (GTV)
at diagnosis was estimated by the maximum GTV diameters (ante-
rior–posterior, latero-lateral, cranio-caudal) using the ellipsoid-
formula (Volume = height width  thickness  p/6). Mean val-
ues for MPD and DVH parameters for both groups were compared.
A double-sided two-independent-samples t-test was used to iden-
tify any signiﬁcant differences. Clinical outcome in terms of overall
survival (OS) and cancer speciﬁc survival (CSS) was measured as
previously described by Pötter et al. [4,5]. A p-value of <0.05 was
considered statistically signiﬁcant. All statistical analyses were
performed using the SPSS 15.0 software (SPSS, Chicago, IL).
Results
Patient and treatment characteristics from matched-pair analysis
Patient characteristics from both groups are presented in Table
1. Three patients with LR had to be excluded because of insufﬁcient
imaging data. Hence, in total 21 patients with LR and 21 patients in
CCLR were available for this study. In all patients except one with
hip prosthesis at least one MRI-based treatment plan was avail-
able. If for some fractions no MRI was available, a CT was used to-
gether with the target volume information from the available MRI.
Median follow-up was 17 months in LR-group and 24 months in
the CCLR group. The distribution of (matched) prognostic factors
waswell balanced in both groups. Therewere no statistically signif-
icant differences in age, histology, FIGO stage, tumour size, regional
lymph node involvement and delivery of concomitant chemother-apy. The mean volume of GTV at diagnosis was 75 cm3 ± 43 and
71 cm3 ± 79 in the LR and CCLR group, respectively (p = 0.841). The
mean volume of HR CTV was 50 cm3 ± 22 and 47 cm3 ± 33 in the
LR and CCLR group, respectively (p = 0.78). The total treatment time
could not be matched and was signiﬁcantly longer in the LR group
(62 vs. 51 days, p = 0.03). In the LR group the application was per-
formed in 17 patients with a tandem-ring applicator, in three pa-
tients with a combination of a tandem and a vaginal cylinder and
in one patient with both tandem/vaginal cylinder and tandem-ring
applicator. Eleven patients received additional interstitial needles.
Overall amean number of 2.5 ± 3 interstitial needles per application
were used in the LR group. In the CCLR group the application was
performed in 17 patients with a tandem-ring applicator, in two pa-
tients with a combination of a tandem and a vaginal cylinder and
two patients with both tandem/vaginal cylinder and tandem-ring
applicator. Fourteen patients received additional needles. Overall a
mean number of 4.5 ± 4 interstitial needles per application were
used in the CCLR group. The difference in the number of the intersti-
tial needles between patients with LR and patients in CCLR was not
statistically signiﬁcant (p = 0.1).Patterns of failure and clinical outcome
In eight patients a central recurrence and in 13 patients a non-
central recurrence were observed. Nine of the non-central recur-
rences were ipsilateral recurrences and four were contralateral
recurrences. Salvage treatment for patients with LR was surgery
(n = 4), reirradiation (n = 3), chemotherapy (n = 9) and no treat-
ment (n = 8). At the time of analysis 19/21 patients in the LR group
had died due to tumour progression. The median time to LR was
10 months and the median time from LR to death was 7 months.
In the CCLR group 6/21 patients died – ﬁve due to distant metasta-
sis and one without any evidence of cervical cancer.
Table 1
Patient characteristics from matched-pair analysis.
Characteristic LR [n = 21] CCLR [n = 21] p
Age [years {mean (range)}] 52 (33–90) 58 (38–85) 0.17
Histology [n]
Squamous cell carcinoma 17 18 0.69
Adenocarcinoma 3 3 1.00
Others 1 0 0.32
FIGO stage [n]
IB 0 1 0.32
IIA 1 0 0.32
IIB 8 9 0.76
IIIB 10 9 0.76
IVA 2 2 1.00
Tumour size [n]
Width < 5 cm 3 3 1.00
WidthP 5 cm 18 18 1.00
Regional lymphnode involvement [n] 12 12 1.00
Concurrent chemotherapy [n] 12 15 0.35
LR – local recurrence, CCLR – continuous complete remission.
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All dose parameters are given in Table 2. TheMPD forHRCTVwas
72 Gy ± 13 Gy for patients in the LR arm and 99 Gy ± 20 Gy for pa-
tients in the CCLR arm (p < 0.01). The MPD for IR CTV was
58 Gy ± 6 Gy for patients in the LR arm and 73 Gy ± 6 Gy for patients
in the CCLR arm (p < 0.01). ThemeanD90 andD100 for HR CTVwere
77 Gy ± 12 Gy and 61 Gy ± 7 Gy for patients with LR and
95 Gy ± 10 Gy and 71 Gy ± 7 Gy for patients in CCLR, respectively
(p < 0.01). The mean D90 and D100 for IR CTV were 64 Gy ± 6 GyTable 2
Dose analysis from matched-pair analysis.
Parameter LR [n = 21] CCLR [n = 21] p
Doses to HR CTV [Gyab10 {mean (st. dev.)}]
MPD 72 (±13) 99 (±20) <0.001
D100 61 (±7) 71 (±7) <0.001
D98 67 (±8) 80 (±8) <0.001
D90 77 (±12) 95 (±10) <0.001
D50 121 (±30) 146 (±20) <0.001
Doses to IR CTV [Gyab10 {mean (st. dev.)}]
MPD 58 (±6) 73 (±6) <0.001
D100 54 (±4) 60 (±5) <0.001
D98 57 (±5) 66 (±6) <0.001
D90 64 (±6) 76 (±6) <0.001
D50 95 (±17) 115 (±13) <0.001
D90 for HR CTV P87 Gy [n] 7 17 –
MPD for HR CTV P87 Gy [n] 3 17 –
LR – local recurrence, CCLR – continuous complete remission, HR CTV – high risk
clinical target volume, IR CTV – intermediate risk clinical target volume, MPD –
mean minimum point dose.
Table 3
Patterns of failure.
No. of patients MPD [Gyab10 {mean (st. dev.)}]
Central recurrence 8 69.5 (±9.9)
True central 2 83.3 (±9.3)
Whole small pelvis 6 65.0 (±4.5)
Non-central recurrence 13 73.5 (±14.8)
Ipsilateral 9 65.6 (±9.2)
Contralateral 4 91.2 (±7.1)
MPD – mean minimum point dose.and 54 Gy ± 4 Gy for patients with LR and 76 Gy ± 6 Gy and
60 Gy ± 5 Gy for patients in CCLR, respectively (p < 0.01).
In the LR arm 7 patients had a D90 for HR CTVP 87 Gy, how-
ever, in only 3 patients the MPD for HR CTV wasP87 Gy. The mean
difference between the D90 for HR CTV and the MPD for HR CTV
was 6 Gy ranging from 5 to 17 Gy.
The mean MPD of HR CTV was 83 Gy ± 10 Gy for true central
recurrences and 65 Gy ± 5 Gy for whole small pelvis recurrences.
The mean MPD of the HR CTV for ipsilateral LR (n = 9) was
66 Gy ± 9 Gy, however, for contralateral LR (n = 4) 91 Gy ± 7 Gy
(Table 3).Discussion
The heterogeneous dose distribution and the steep dose fall off
make dose reporting a critical issue in brachytherapy. For cervical
cancer it was shown that the use of DVH parameters related to the
individual target volume (D90, D100 for HR CTV) is more appropri-
ate in predicting local control than the use of point doses (Point
A + B) related to the applicator [15,16]. However, these DVH
parameters have limitations: The D100 for HR CTV reﬂecting the
minimum dose within the target is known to be highly inﬂuenced
by uncertainties [8,9]. Any part/voxel of the target volume contrib-
utes to the D100 independently of its clinical relevance. Further on,
the localization of the minimum dose may vary in the target espe-
cially if multiple applications with different implants are neces-
sary. The D90 for HR CTV reﬂecting the minimum dose of the
most irradiated 90% of the target was reported to be a clinically
more reliable parameter. However, since the D90 does not refer
to the whole target, low dose regions within the target represent-
ing major residual tumour may be hidden. Based on this back-
ground the study was initiated to investigate for the ﬁrst time
the local dose in the area of recurrence in patients with locally re-
lapsed cervical cancer treated by EBRT (+/ chemotherapy) and
IGABT. The dose in the area of LR was assessed using a newly intro-
duced methodology and was compared to the dose derived from
patients in CCLR within a matched pair analysis. Additionally sev-
eral DVH parameters were analysed. It has to be stated that the
MPD is rather an approximation representing a surrogate than a
precise value. No information in regard of the volume the low dose
region can be derived from the MPD. The mean MPD in the area of
the LR was 72 Gy for HR CTV and 58 Gy for IR CTV. In contrast, the
meanMPD for patients in CCLR was 99 Gy for HR CTV and 73 Gy for
IR CTV. This difference in dose between patients in LR and CCLR
was statistically signiﬁcant. The value of 99 Gy for HR CTV in pa-
tients in CCLR was high, which was mainly related to loaded inter-
stitial needles at or close to the HR CTV border, resulting in high
physical doses and even higher biologically normalized doses.
In accordance to the MPD statistically signiﬁcant differences be-
tween the LR and CCLR group were found for all investigated DVH
parameters for both HR CTV and IR CTV. The differences were most
pronounced for the D50 – with correspondingly very high standard
deviations – whereas the least difference was found for the D100.
The intention to investigate the D50 was based on the assumption
that high dose regions within the target may have an additional
impact on the local outcome. However, in this limited material it
was not possible to detect an independent importance of the
D50. The D98 seems to be an interesting alternative to the D100
since uncertainties in the DVH sampling might be less inﬂuencing.
Further investigations will be necessary to determine the role of
the D98. Regarding the various DVH parameters it seems that cur-
rently the D90 remains the most reliable indicator for predicting
local tumour control.
All of the 13 patients in the LR group with a D90 for HR CTV
<87 Gy showed a MPD of <87 Gy. According to this agreement, in
472 Local recurrences in cervical cancerthese patients, it seems that the low dose detected by the DVH
parameter could also be topographically related to the area of LR.
Subsequently the remaining seven patients with LR showed a D90
for HR CTVP 87 Gy. However, in four out of these seven patients
with aD90 forHRCTVP 87 Gy theMPD forHRCTVwas<87 Gy. This
indicates that areaswith a low dose can occur evenwith high values
of the D90 for HR CTV, if these low dose regions are systematically
located in the missing 10% of the target volume. In total, differences
of up to 17 Gywere found between the D90 for HR CTV and theMPD
for HR CTV in the LR group. In contrast, 17 patients in the CCLR arm
had a D90 and MPD for the HR CTVP 87 Gy.
Thirteen of 21 patients from the LR group were treated in the
‘‘learning period’’ as described by Pötter et al. [4,5] from 1998 to
2001. In this period – even though MRI based treatment planning
was performed – patients were treated without prospective con-
touring using a standardized target deﬁnition and only with very
limited dwell time optimization for increasing the target coverage.
The use of additional interstitial needles in order to increase and
shape the treated volume was limited. Although sometimes high
D90 have been achieved, the spatial dose distribution was not opti-
mized appropriately to the target volume. The nonstandardized
fractionation scheme varied in this period and caused for several
cases a prolonged treatment time. Therefore, the total treatment
time could not be matched to patients treated within the ‘‘protocol
period’’ [4,5] and was statistically signiﬁcantly longer in LR group
than in the CCLR group. This is a limitation of the study, however,
this means that the differences in delivered dose in time for the
two patient groups are probably even more pronounced due to
radiobiological effects.
The analysis of the different patterns of failure revealed that
whole small pelvis recurrences and non-central ipsilateral recur-
rences had a mean MPD of 65 Gy. In these patients it seems that
the occurrence of the local failure was mainly related to low dose
regions within the target. In contrast, true central recurrences and
non-central contralateral recurrences had a mean MPD ranging
from 83 Gy to 91 Gy. No substantial low dose regions could be
found in these patients. It can be assumed that in these cases other
(biological?) factors than dose may be predominant, which would
be in accordance with the literature about cervical cancer indicat-
ing radioresistance [17].
In regard of the similar volume of the HR CTV in the LR and CCLR
groups, the main reasons for the differences in dose between the
two groups can be found in the systematic and optimized applica-
tion of interstitial needles in the CCLR group leading to better cov-
erage of the target volume in patients with large target volumes
and/or unfavourable topography of the target.Conclusions
This study demonstrated signiﬁcant differences in local out-
come according to the delivered dose. In 85% of the LRs systematic
low dose regions with less than 87 Gy were found at the HR CTV
contour. Systematic low dose regions leading to LR could be de-
tected even if a D90 for HR CTVP 87 Gy was applied. However,
regarding the various DVH parameters the D90 remains the most
reliable predictor for local tumour control. In addition to DVH
parameters, inspection of the spatial dose distribution remains a
key point in dose prescription.Conﬂict of interest notiﬁcation
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